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A B S T R A C T
Background
Penetrating keratoplasty is a corneal transplantation procedure in which a full-thickness cornea from the host is replaced by a graft
from a donor. The use of various immunosuppressants to prevent graft rejection, the most common cause of graft failure in the late
postoperative period, is increasing.
Objectives
To assess the effectiveness of immunosuppressants in the prophylaxis of corneal allograft rejection after high- and normal-risk kerato-
plasty.
Search methods
We searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (2015, Issue 4), Ovid MEDLINE,
Ovid MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to
May 2015), EMBASE (January 1980 to May 2015), China National Knowledge Infrastructure (CNKI) (January 1913 to February
2015), VIP database (January 1989 to February 2015), Wanfang Data (www.wanfangdata.com) (January 1990 to February 2015),
the ISRCTN registry (www.isrctn.com/editAdvancedSearch), ClinicalTrials.gov (www.clinicaltrials.gov), and the World Health Orga-
nization (WHO) International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en). We did not use any date or
language restrictions in the electronic searches for trials. We last searched the English language databases on 18 May 2015 and the
Chinese language databases on 20 February 2015.
Selection criteria
We included all randomised controlled trials (RCTs) assessing the use of immunosuppressants in the prevention of graft rejection,
irrespective of publication language.
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Data collection and analysis
We used standard procedures expected by Cochrane. The primary outcome was clear graft survival at 12 months after penetrating
keratoplasty. Secondary outcomes included graft rejection, best-corrected visual acuity, and quality of life. We defined ’high-risk
keratoplasty’ as repeat keratoplasty and other indications of reduced graft survival.
Main results
We included six studies conducted in Germany (three studies), Iran, India, and China. Three studies were conducted in people
undergoing high-risk keratoplasty and investigated three different comparisons: systemic mycophenolate mofetil (MMF) versus no
MMF; systemic MMF versus systemic cyclosporine A (CsA); and topical CsA versus placebo. One study compared topical tacrolimus
to topical steroid in people with normal-risk keratoplasty, and two studies compared topical CsA to placebo in people experiencing
graft rejection after normal-risk keratoplasty. Overall, we considered the trials to be at unclear or high risk of bias.
MMF may not improve clear graft survival (risk ratio (RR) 1.06, 95% confidence interval (CI) 0.84 to 1.33, 1 RCT, 87 participants,
low-quality evidence) but may reduce the risk of graft rejection (RR 0.49, 95% CI 0.22 to 1.08, 1 RCT, 87 participants, low-quality
evidence) compared to no MMF. Visual acuity was not reported.
In 1 study of 52 people comparing systemic MMF and systemic CsA, there were no graft failures in the first year of follow-up. Data
from the longest follow-up (three years) suggest that there may be little difference in the effect of these two treatments on clear graft
survival (RR 1.10, 95% CI 0.90 to 1.35, low-quality evidence). There was low-quality evidence of an increased risk of graft rejection
with systemic MMF compared to systemic CsA, but with wide CIs compatible with increased risk with systemic CsA (RR 1.48, 95%
CI 0.56 to 3.93, low-quality evidence). Visual acuity was not reported.
One study of 84 people comparing topical CsA to placebo did not report clear graft survival at 1 year, which suggests that all grafts
survived to 1 year. This study suggests that the use of topical CsA probably leads to little or no difference in graft rejection (RR 1.00,
95% CI 0.39 to 2.58, moderate-quality evidence). At one year, the mean difference (MD) between the two groups in visual acuity was
0.07 (95% CI -0.01 to 0.15, moderate-quality evidence).
Topical CsA probably does not have an effect on clear graft survival in people experiencing graft rejection after normal-risk keratoplasty
compared to placebo (RR 1.03, 95% CI 0.96 to 1.10, 2 RCTs, 283 participants, moderate-quality evidence). There were inconsistent
findings on graft rejection, with one study reporting a reduced incidence of graft rejection in the CsA group (RR 0.35, 95% CI 0.14
to 0.87, 230 participants) but the other study reporting a higher average number of episodes of graft rejection in people treated with
CsA (MD 1.30, 95% CI 0.39 to 2.21, 43 participants). Overall, we judged this to be low-quality evidence due to risk of bias and
inconsistency. There was no evidence for a difference in visual acuity between the 2 groups at final follow-up (approximately 18 months,
range 2 to 33 months) (MD 0.04, 95% CI -0.10 to 0.18, 1 RCT, 43 participants, low-quality evidence).
In 1 study comparing topical tacrolimus to topical steroid, the graft survived in all of the 12 treated participants and 20 control
participants at 6 months. Graft rejection was rare (0 out of 12 versus 2 out of 20) (RR 0.32, 95% CI 0.02 to 6.21, low-quality evidence).
Visual acuity was not reported.
None of the studies reported on quality of life. We identified an unpublished trial of basiliximab (Simulect) (NCT00409656), probably
completed in 2005.
Authors’ conclusions
Current evidence on the effect of immunosuppressants in the prevention of graft failure and rejection after high- and normal-risk
keratoplasty is largely low quality because the number of trials was limited, and, in general, the trials were small and at risk of bias.
Future trials should be large enough to detect important clinical effects, conducted with a view to minimising the risk of bias, and they
should measure outcomes important to patients.
P L A I N L A N G U A G E S U M M A R Y
Immunosuppressants to prevent corneal graft rejection after penetrating keratoplasty
Background
The cornea is the transparent front part of the eye that if damaged, can be replaced by a corneal transplant (keratoplasty) using
healthy cornea tissue from a donor. A penetrating keratoplastyinvolves replacing all the damaged cornea. It is necessary to prevent
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the transplanted material (graft) from being rejected. The current strategies for preventing graft rejection are topical and oral steroids.
The use of cyclosporine A (CsA), tacrolimus, mycophenolate mofetil (MMF), sirolimus, and leflunomide is increasing. However, the
benefits and adverse reactions of these immunosuppressants have not yet been systematically reviewed.
Search date
The evidence is up to date to May 2015.
Key findings
We included six randomised controlled trials that enrolled a total of 561 people. The trials were conducted in Germany (three trials),
Iran, India, and China.
In people with high-risk keratoplasty, one study compared systemic MMF with placebo, one study compared systemic MMF with
systemic CsA, and one study compared CsA eye drops versus placebo.
In people with normal-risk keratoplasty, one study compared tacrolimus eye drops to steroid eye drops, and two studies compared
CsA eye drops to placebo in people experiencing rejection after keratoplasty. All studies reported clear graft survival, incidence of graft
rejection, and adverse effects.
We are uncertain as to the effects of immunosuppressants in the prevention of graft failure and rejection after high- and normal-risk
keratoplasty, as the number of trials is limited, and, in general, the trials are small and at risk of bias. Future trials should be large
enough to detect important clinical effects, conducted with a view to minimising the risk of bias, and they should measure outcomes
important to patients.
Study funding sources
Three of the studies were supported by the pharmaceutical industry.
Quality of evidence
We judged the quality of the evidence to be low to moderate. There was risk of bias in the included studies; the results were sometimes
imprecise because of the small number of studies and small number of people enrolled in these studies; and in some analyses the results
of individual trials were inconsistent.
B A C K G R O U N D
Description of the condition
Penetrating keratoplasty is a corneal transplantation procedure in
which a full-thickness cornea from the host is replaced by a graft
from a donor. It has been performed in many eye diseases, includ-
ing pseudophakic corneal oedema, keratoconus, aphakic corneal
oedema, and stromal corneal dystrophies (Dobbins 2000; Liu
1997; Ramsay 1997). Survival of first-time grafts is 90% at 5 years
and 82% at 10 years, with reported allograft rejection rates follow-
ing penetrating keratoplasty ranging from 5% to 18% (Tabbara
2007). Initial regrafts have significantly lower 5- and 10-year sur-
vival rates, 53% and 41%, respectively (Thompson 2003).
The risk factors for graft failure after keratoplasty are young recip-
ient age, the number of previous grafts, history of previous ante-
rior segment surgery, preoperative glaucoma, quadrants of ante-
rior synechiae, quadrants of stromal vessels, a primary diagnosis
of chemical burn, and blood group ABO incompatibility. In such
cases, known as high-risk keratoplasty, the graft rejection rate may
be higher than 60% (Maguire 1994).
Prevention of corneal allograft rejection
The eye has properties that permit the long-term survival of tissue
grafts that are normally rejected at extraocular sites. This ocular
immune privilege was originally attributed to a putative seques-
tration of antigens in the eye as a result of the conspicuous absence
of intraocular lymphatic drainage channels (Niederkorn 2003).
However, a recent multivariate analysis suggests there is no dif-
ference between the long-term outcomes of corneal transplanta-
tion and those of other forms of transplantation (Williams 2006).
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The anterior segment of the eye is still regarded as an immune-
privileged site because of the absence of vascular and lymphatic
supply to the cornea. Cell-mediated immunity in corneal allograft
rejection can result from the activation of limbal Langerhans cells
and from T-cells activation by antigens released in the aqueous
humor of the anterior chamber (Yamagami 2005). Nevertheless,
the immunology of corneal transplantation is not fully understood
(Perez 2013). Furthermore, corneal graft rejection remains the
most common cause of graft failure in the late postoperative pe-
riod, and prophylaxis for allograft rejection is needed (Ing 1998).
Description of the intervention
A variety of strategies to prevent corneal allograft rejection have
been explored and include the use of several immunosuppres-
sants through various delivery systems; human leukocyte antigens
matching; and manipulation of antigen expression. Immunosup-
pressants include steroids, cyclosporine A (CsA), tacrolimus, my-
cophenolate mofetil (MMF), sirolimus, and leflunomide. Topical
and oral steroids are currently the gold standard for routine use
in the prevention of graft rejection (Hill 1991; Randleman 2006;
Tabbara 2007), and the use of topical cyclosporine for routine
management of high-risk grafts is increasing (Randleman 2006).
CsA is a fungal protein that has a high degree of specificity for
T-cell lymphocytes and as a calcineurin inhibitor prevents T-cell-
mediated immune responses. It is believed that systemic CsA sig-
nificantly increases the rate of graft survival in high-risk corneal
transplantation when used prophylactically following transplan-
tation. However, this therapy also carries significant risks, includ-
ing hypertension, renal toxicity, hepatotoxicity, neurotoxicity (Hill
1989; Hill 1994), and post-transplant lymphoproliferative dis-
orders (Algros 2002). Although evidence on the effectiveness of
topically administered CsA in the prevention of graft rejection is
increasing (Belin 1990), studies have yielded inconsistent results.
For example, investigators found that the use of a combination of
topical CsA and steroids is better than steroids alone in preventing
episodes of rejection (Cosar 2003; Inoue 2000). However, other
investigators found that topical CsA did not demonstrate any sig-
nificant improvement in preventing corneal graft rejection (Price
2006; Shepherd 1980).
Tacrolimus has been shown to be effective in preventing corneal
allograft rejection (Reinhard 2005; Sloper 2001), causing a lower
incidence of side effects related to toxicity or over immunosup-
pression at a much lower dosage than CsA (Reis 1998b). System-
atic adverse effects such as hypertension and renal toxicity may be
encountered with oral tacrolimus (Sloper 2001).
MMF is thought to be a safe and effective immunosuppressive
agent following renal transplantation due to less nephrotoxicity
(Guerra 2007; Land 2005), but is teratogenic and is unsafe for
use in pregnant women (Jackson 2009; Klieger-Grossmann 2010).
MMF has been shown to be as effective as CsA in preventing acute
rejection following high-risk corneal transplantation (Reinhard
2005; Reis 1999), but inferior to systemic tacrolimus in preventing
graft rejection (Reis 1998a).
Sirolimus is a bacterial macrolide with both antifungal and im-
munosuppressive properties. It is commonly used in conjunction
with CsA or tacrolimus after solid-organ transplantation. Simi-
lar to MMF, sirolimus is fetotoxic, although not teratogenic, and
should be usedwith caution in corneal transplantation in pregnant
women (Guerra 2007).
How the intervention might work
Immunosuppressants prevent corneal graft rejection by inhibiting
the immunity of the host. Different drugs have different targets.
The mechanism of CsA prophylaxis of corneal graft rejection is
mainly by selectively inhibiting cellular immunity, which primar-
ily inhibits the proliferation and action of T-cells (Utine 2010).
MMF prevents the replication of T- and B-lymphocytes by in-
hibiting the de novo pathway of purine synthesis (Siconolfi 1996).
Tacrolimus, a calcineurin inhibitor, is a macrolide antibiotic with
potent immunosuppressive activity (Pillans 2006). Steroids have
an antiproliferative function (Taylor 2005).
Why it is important to do this review
Immunosuppressants are widely used for the prophylaxis of
corneal graft rejection after high- and normal-risk keratoplasty.
However, the benefits and adverse reactions from their use have
not yet been systematically reviewed.
O B J E C T I V E S
Our primary objective was to assess the effectiveness of immuno-
suppressants in the prophylaxis of corneal allograft rejection after
high- and normal-risk keratoplasty.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) only.
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Types of participants
We included people undergoing high- and normal-risk kerato-
plasty and evaluated them as two separate groups. We defined the
term ’high-risk keratoplasty’ as repeat keratoplasty, graft position
close to the limbus, presence of three or four quadrants with deep
vascularisation, transplantation of a highly immunogenic graft (for
example central limbo-keratoplasty), severe atopic dermatitis, and
steroid-response glaucoma.
Types of interventions
We included trials in which systemic or topical immunosuppres-
sants such as CsA, tacrolimus, sirolimus, and MMF were com-
pared to placebo, corticosteroids, or other immunosuppressants.
Types of outcome measures
Primary outcomes
1. Clear graft survival 12 months after penetrating
keratoplasty.
Secondary outcomes
1. Graft rejection 12 months after penetrating keratoplasty.
We defined rejection as any immune reaction requiring a change
in therapy.
2. Best-corrected visual acuity.
3. Quality of life measured using a validated questionnaire.
4. Cost-effectiveness. This includes the cost of the drugs and
other palliative medications, the need for bed rest or
hospitalisation versus outpatient care, and the length of hospital
stay.
5. Adverse effects
i) Epithelial keratitis
ii) High intraocular pressure as defined by study
investigators
iii) Major calcineurin-inhibitor toxicity (e.g. new-onset
diabetes or renal failure)
iv) Minor calcineurin-inhibitor toxicity (e.g. tremor,
gingivitis, or hirsutism)
v) Dose reductions due to adverse events
vi) Withdrawals and dropouts due to adverse events
We measured most outcomes during a 1-year, 2-year, 5-year, and
10-year follow-up where possible. For those studies where the
aforementioned follow-up was not available even after correspon-
dence with the principal investigator, we included the nearest time
point available in the general and subgroup analyses.
Search methods for identification of studies
Electronic searches
We searched CENTRAL (which contains the Cochrane Eyes
and Vision Group Trials Register) (2015, Issue 4), Ovid MED-
LINE, Ovid MEDLINE In-Process and Other Non-Indexed Ci-
tations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (Jan-
uary 1946 to May 2015), EMBASE (January 1980 to May
2015), China National Knowledge Infrastructure (CNKI) (Jan-
uary 1913 to February 2015), VIP database (January 1989 to
February 2015),WanfangData (www.wanfangdata.com) (January
1990 to February 2015), the ISRCTN registry (www.isrctn.com/
editAdvancedSearch), ClinicalTrials.gov (www.clinicaltrials.gov),
and the World Health Organization (WHO) International Clini-
cal Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/
en). We did not use any date or language restrictions in the elec-
tronic searches for trials. We last searched the English language
databases on 18May 2015 and the Chinese language databases on
20 February 2015.
See: Appendices for details of search strategies for CENTRAL
(Appendix 1), MEDLINE (Appendix 2), EMBASE (Appendix
3), China National Knowledge Infrastructure (CNKI) (Appendix
4), VIP database (Appendix 5), Wanfang Data (Appendix 6), IS-
RCTN (Appendix 7), ClinicalTrials.gov (Appendix 8), and the
ICTRP (Appendix 9).
Searching other resources
We searched reference lists of identified trial reports to find addi-
tional trials. We also searched the Social Science Citation Index to
find studies that had cited the identified trials.
Data collection and analysis
Selection of studies
Two review authors (MA, TXW) scanned the titles, abstracts, and
keywords of every record retrieved to find studies that met our in-
clusion criteria. We retrieved full-text copies of the studies for fur-
ther assessment if the information given suggested that the studies:
1. included participants after penetrating keratoplasty;
2. compared immunosuppressants such as CsA, tacrolimus,
and MMF with corticosteroids only;
3. assessed one or more relevant clinical outcome measures;
4. used random allocation for the comparison groups.
After reviewing the full text, we included only those studies that
fulfilled the inclusion criteria. We excluded studies if they used
a false randomisation procedure or included participants com-
plicated with other diseases. We listed excluded studies in the
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Characteristics of excluded studies section with reasons for exclu-
sion.
Any disagreements were resolved through discussion or, if re-
quired, through consultation with a third review author.
Data extraction and management
Two review authors (MA, TXW) independently extracted data
concerning details of study population, intervention used, and
outcomes using a data extraction form and then entered into
RevMan 2014. The form included the following items.
1. General information: setting, country, year of publication,
sponsor
2. Trial characteristics: design, duration of follow-up, method
of randomisation, allocation concealment, masking (blinding)
(participants, people administering treatment, outcome assessors)
3. Intervention(s): intervention(s) (dose, route, timing),
comparison intervention(s) (dose, route, timing), co-
medication(s) (dose, route, timing)
4. Participants: exclusion criteria, total number and number in
comparison groups, age (adults), baseline characteristics,
diagnostic criteria, similarity of groups at baseline (including any
comorbidity), assessment of compliance, withdrawals/losses to
follow-up (reasons/description), subgroups
5. Outcomes: outcomes specified in this review, any other
outcomes assessed, other events, length of follow-up, quality of
reporting of outcomes
6. Results: for outcomes (including a measure of variation)
and times of assessment
MA and TXW independently abstracted original reports of trial
results. We contacted authors of the primary studies for further
information. There were no disagreements in this step.
For binary outcomes, we extracted the number of events and total
number in each group. For continuous outcomes, we extracted
the mean, standard deviation, and sample size of each group.
Assessment of risk of bias in included studies
We assessed the quality of reporting for each trial based largely on
the criteria specified by Chapter 8 of the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). See Appendix
10 for further details.
We also planned to explore the influence of individual quality
criteria in a sensitivity analysis.
Measures of treatment effect
For dichotomous data, we used risk ratios and 95% confidence
intervals. For continuous data, we used mean difference and 95%
confidence intervals to express the effects if we could extract the
data as mean and standard deviation.
Unit of analysis issues
Participants were randomly allocated to treatment in all studies.
In two studies it was stated that one eye per person was included
(Javadi 2010; Sinha 2010); in the other studies this was not clear.
Dealing with missing data
We assessed and reported the presence or absence or an intention-
to-treat (ITT) analysis in the following way (ITT analysis refers
to the analysis of outcomes based on the treatment arm to which
participants were randomly allocated, rather than the treatment
they actually received):
• Yes: Specifically reported by authors that ITT analysis was
undertaken and confirmed on study assessment.
• Yes: Not specifically reported, but confirmed on study
assessment.
• No: Not reported and lack of ITT analysis confirmed on
study assessment (participants who were randomised were not
included in the analysis because they did not receive the study
intervention, they withdrew from the study, or were not included
because of protocol violation).
• No: Stated but not confirmed on study assessment.
• Unclear: Not reported and not clear from study assessment.
Assessment of heterogeneity
We examined heterogeneity by the Chi2 test, and the significance
was set at P greater than 0.1; I2 is used to estimate total variation
across studies that is due to heterogeneity using percentages. I2 less
than 40% is considered as not having important heterogeneity,
30%to60%asmoderate heterogeneity, 50%to90%as substantial
heterogeneity, and 75% to 100% as considerable heterogeneity
as outlined in Chaper 9 of the Cochrane Handbook for Systematic
Reviews of Interventions (Deeks 2011). If there was evidence of
heterogeneity, we planned to explore it and perform subgroup
analysis to determine the possible reason.We performed sensitivity
analysis to explore whether or not the heterogeneity was due to
low-quality trials. If so, we excluded the lowest quality trials.
Assessment of reporting biases
We did not assess potential publication bias using a funnel plot
as planned as we included only six studies. See Chapter 10 of the
Cochrane Handbook for Systematic Reviews of Interventions (Sterne
2011).
Data synthesis
Weperformed statistical analyses according to the statistical guide-
lines in Chapter 8 of theCochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011).
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When data were reported in various forms that could not easily
be converted into a standard measure, we summarised the data in
a narrative format, and analysed different comparisons separately.
We included data in a meta-analysis if they were of sufficient qual-
ity and sufficiently similar. We used a fixed-effect model because
less than three trials were included in each analysis.
Subgroup analysis and investigation of heterogeneity
We did not perform subgroup analyses in this review. In future
updates we plan to conduct subgroup analysis with the following:
• Normal- versus high-risk keratoplasty
• Different dosage of immunosuppressants
Sensitivity analysis
We were unable to conduct our planned sensitivity analysis due to
only one or two studies belonging to each subgroup. If more trials
are included in future updates of this review, we plan to conduct
sensitivity analysis to assess how robust the review results are to
key decisions and assumptions made during the review. We will
repeat analysis of data with the following adjustments.
1. Exclusion of studies with high risk of bias; studies with low
risk of bias were defined as having adequate allocation
concealment and a ’reasonably expected loss to follow-up’
classified as less than 20%, given the stated importance of
attrition as a quality measure (Tierney 2005).
2. Exclusion of unpublished studies.
3. Comparing the difference between the combined analysis
results from the random-effects model and the fixed-effect model.
Summary of findings table
In amodification to our published protocol, we planned to prepare
a ’Summary of findings’ table presenting relative and absolute risks
for the outcomes listed below. However, as the data were limited
for each comparison, we did not include such a table in the current
version of the review.
We graded the overall quality of the evidence for each outcome
using the GRADE classification (www.gradeworkinggroup.org/).
In future updates, we will include the following outcomes in the
’Summary of findings’ table.
1. Clear graft survival
2. Graft rejection
3. Best-corrected visual acuity
4. Quality of life
5. Adverse effects
Follow-up: 12 months after penetrating keratoplasty
R E S U L T S
Description of studies
Results of the search
The electronic searches yielded a total of 6660 records. The Tri-
als Search Co-ordinator ran the electronic searches and identified
577 records, and we ran searches on the VIP and China National
Knowledge Infrastructure Chinese databases and identified 6023
records. See Figure 1 for details of the screening process of the
search results. We obtained full-text records of 20 reports for fur-
ther investigation. We included 9 reports of 6 studies and excluded
10 reports of 9 studies. See Characteristics of included studies;
Characteristics of excluded studies. We have also included one
study in Ongoing studies that is completed but the results have
not yet been published (NCT00409656). We tried but failed to
make contact the investigators of this study to obtain the data; we
will add this study to the review if the data becomes available.
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Figure 1. Study flow diagram
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Included studies
Six studies met our inclusion criteria (Birnbaum 2009; Javadi
2010; Reinhard 2001; Reinhard 2005; Sinha 2010; Zhang 2009).
See Table 1 and Characteristics of included studies for further
information.
Study design
All studies used a parallel-group design. The unit of allocation
for treatment was individual participants, although it was not al-
ways clear how many eyes were included. Birnbaum 2009, Javadi
2010, Reinhard 2001, and Sinha 2010 were single-centre studies;
Birnbaum 2009 and Zhang 2009 were multicentre studies; for
Reinhard 2005 this was unclear.
Participants
Three studies were conducted in Germany (Birnbaum 2009;
Reinhard 2001; Reinhard 2005), one study in Iran (Javadi 2010),
one study in India (Sinha 2010), and one study in China (Zhang
2009).
Three studies enrolled a total of 238 participants undergoing high-
risk keratoplasty (Birnbaum 2009; Reinhard 2001; Sinha 2010).
One study enrolled 40 participants undergoing normal-risk ker-
atoplasty (Reinhard 2005).
Two studies enrolled a total of 283 participants experiencing graft
rejection after keratoplasty (Javadi 2010; Zhang 2009).
Interventions
Birnbaum 2009 comparedMMF versus no systemic immunosup-
pression (inmidterm). All participants in both groups received sys-
temic and topical corticosteroids: fluocortolone at 1 mg/kg body
weight per day, tapered over three weeks, and prednisolone acetate
1% eye drops five times a day, tapered over five months.
Javadi 2010 compared 2% topical CsA versus placebo. Partici-
pants were randomly given 2% topical CsA or placebo four times
a day for six months in addition to corticosteroid treatment. Based
on the severity of graft rejection reaction, corticosteroid treatment
consisted of 0.1% topical betamethasone every one hour during
waking hours with its ophthalmic ointment during sleep, alone
or in combination with 1 mg/kg oral prednisolone for two weeks.
The topical corticosteroidwas gradually tapered off over twoweeks
after resolution of the rejection episode, whichwas defined as com-
plete clearance of keratic precipitates or anterior chamber reaction,
or both. Graft rejection episodes recurring after the termination
of CsA were treated with corticosteroids as usual.
Reinhard 2001 compared systemic MMF versus systemic CsA.
All participants except those with steroid-induced glaucoma re-
ceived corticosteroids systemically (1 mg/kg body weight fluocor-
tolone, tapered within three weeks postoperatively) and topically
(five drops prednisolone acetate 1% daily after epithelial consoli-
dation, tapered within five months).
Reinhard 2005 compared topical tacrolimus versus topical
steroids. Twenty participants were treated with tacrolimus 0.06%
three times topically per day for six months postoperatively
(tacrolimus group). An additional 20 participants received 5 drops
of prednisolone acetate 1% tapered within six months (control
group). All participants received 1 mg/kg body weight per day
of systemic fluocortolone, tapered within three weeks postopera-
tively.
Sinha 2010 compared 2% topical CsA (in vehicle polyvinyl al-
cohol) in the experimental group versus 1.4% polyvinyl alcohol
drops in control group. Both groups also received corticosteroid
eye drops after surgery.
Zhang 2009 compared 1% CsA eye drops versus control. Both
groups also received 1% dexamethasone eye drops.
Outcome measures
All studies reported clear graft survival, immune reactions causing
rejection, and side effects. No study reported best-corrected visual
acuity, quality of life, or cost-effectiveness.
Only three studies reported details of the postoperative visits. One
study scheduled these visits after 1, 3, 6, 9, 12, 24, and 36 months
(Reinhard 2001). In another study they were daily in the first week
and after 2, 3, 6, 9, 12, 18, and 24 months (Birnbaum 2009).
Reinhard 2005 did not describe the visit time in detail and only
stated follow-up time of tacrolimus group and steroid group as 5.8
to 14.8 and 9.1 to 13.3 months, respectively.
Excluded studies
We excluded nine studies because although the authors used the
term “randomly allocated patients” in their text, they were not real
RCTs (He 1999; Liu 2007; Lu 2009; Reinhard 1999; Wu 2001;
Xi 2003; Ye 2004; Zhao 2005; Zhou 2008). We telephoned the
authors of these articles for clarification on this point. One study
included participants with different conditions and was therefore
excluded (Reinhard 1999). See Characteristics of excluded studies
for further information.
Risk of bias in included studies
The risk of bias is described below and summarised in Figure 2
and Figure 3.
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Random sequence generation
All included trials stated that they “randomly allocated the par-
ticipants”, but only two studies described adequate measures for
generating the allocation sequence. In Zhang 2009 they used a
random numbers table and in Sinha 2010, they used computer-
generated random numbers with a block randomisation strategy.
Allocation concealment
None of the studies reported on the use of allocation concealment.
Blinding
Blinding (masking) was performed in three studies (Javadi 2010;
Sinha 2010; Zhang 2009).
In Javadi 2010, the participants and the ophthalmologist who
analysed the results were unaware of the type of drops.
In Sinha 2010, to eliminate assessment bias, the ocular pharmacol-
ogist was masked to the outcome variables. Also, the investigator
measuring the outcome variables was masked to the nature of the
drug therapy.
In Zhang 2009, dedicated personnel were responsible for main-
taining masking and keeping the allocation table hidden, thus
both participants and outcome assessor were masked.
The remaining three studies did not provide any information
aboutmasking (Birnbaum 2009; Reinhard 2001; Reinhard 2005).
Incomplete outcome data
Four studies had participants who did not complete the study.
In Birnbaum 2009, 11 participants withdrew from the study: 7 in
theMMFgroup and4 in the control group.Of the 11 participants,
9 withdrew due to protocol deviation, 2 due to side effects from
the MMF.
In Javadi 2010, one participant was excluded because of intoler-
ance to the medication given.
In Reinhard 2001, premature withdrawal from immunosuppres-
sive prophylaxis occurred in two participants in the CsA group
(one case of severe gingival hyperplasia, one of hepatotoxicity), and
in two participants in theMMF group (one diagnosis ofHodgkin’s
lymphoma one month after keratoplasty, one case of dermatolog-
ical problems in a participant with severe atopic dermatitis).
In Reinhard 2005, premature withdrawal from the drug occurred
in eight participants in the tacrolimus group due to local side
effects, and all the participants completed the study in accordance
with the protocol.
There were no exclusions in Sinha 2010.
Zhang 2009 used ITT analysis and reported 1 case where treat-
ment was not completed in the CsA group (1 out of 120) and 9
cases in the control group (9 out of 120). The other studies did
not report the use of ITT analysis.
Selective reporting
The outcomes in the methods section of the study reports were
reported in detail, but we were unable to check the protocols of the
included studies. We therefore judged the risk of reporting bias as
unclear.
Other potential sources of bias
A potential conflict of interest may be present in Sinha 2010 as the
trialists themselves prepared the 2% CsA drops in 1.4% polyvinyl
alcohol. We found no other potential sources of bias in the other
studies.
Effects of interventions
We considered adverse effects separately at the end of this section.
Systemic MMF versus no MMF in people undergoing
high-risk keratoplasty
One study compared MMF and no MMF in 98 participants (87
followed up) undergoing high-risk keratoplasty with an average
follow-up of 34.9 ± 16.3 months (Birnbaum 2009) (Table 2).
Results of this study suggest that MMF may not improve clear
graft survival (risk ratio (RR) 1.06, 95% confidence interval (CI)
0.84 to 1.33), but may reduce the risk of graft rejection (immune
reactions) (RR 0.49, 95% CI 0.22 to 1.08).
We judged this to be low-quality evidence, downgrading for risk
of bias and imprecision.
Visual acuity, quality of life, and costs were not reported.
Systemic MMF versus systemic CsA in people
undergoing high-risk keratoplasty
One study compared systemic MMF and systemic CsA in 52 par-
ticipants with high-risk keratoplasty with three years follow-up
(Reinhard 2001) (Table 3).
There were no graft failures in the first year of follow-up. Data
from the longest follow-up (three years) suggests that there may be
little difference in the effect of these two treatments on clear graft
survival (RR 1.10, 95% CI 0.90 to 1.35). There was low-quality
evidence of an increased risk of graft rejection with systemicMMF
compared to systemic CsA, but with wide CIs compatible with
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increased risk with systemic CsA (RR 1.48, 95% CI 0.56 to 3.93,
low-quality evidence).
We judged this to be low-quality evidence, downgrading for risk
of bias and imprecision.
Visual acuity, quality of life, and costs were not reported.
Topical CsA versus placebo in people undergoing
high-risk keratoplasty
One study compared topical CsA to placebo in 84 participants
undergoing high-risk keratoplasty (Sinha 2010) (Table 4, Table
5).
The study did not report clear graft survival at one year, which
suggests that all grafts survived to one year. Results of this study
suggest that topical CsA probably leads to little or no difference in
graft rejection (RR 1.00, 95% CI 0.39 to 2.58, moderate-quality
evidence).
At one year, the mean difference (MD) between the two groups
in visual acuity was 0.07 (95% CI -0.01 to 0.15).
We judged this to be moderate-quality evidence, downgrading for
imprecision.
Quality of life and costs were not reported.
Topical CsA versus placebo in people experiencing
graft rejection after normal-risk keratoplasty
Two studies compared topical CsA versus placebo in participants
experiencing graft rejection after normal-risk keratoplasty (Javadi
2010; Zhang 2009). Average follow-up was 16 months in Javadi
2010 and 6 months in Zhang 2009.
Topical CsA probably does not have an effect on clear graft survival
(RR 1.03, 95% CI 0.96 to 1.10; participants = 283; studies = 2;
I2 = 34%) (Analysis 1.1). We judged this to be moderate-quality
evidence, downgrading for risk of bias.
Evidence from Zhang 2009 suggests that topical CsA probably
reduces the incidence of graft rejection (RR 0.35, 95% CI 0.14
to 0.87) (Table 6). Javadi 2010 did not report the incidence of
graft rejection but reported that participants treated with CsA on
average had 2.7 (standard deviation (SD) 1.8) episodes of graft
rejection compared to 1.4 (SD 1.2) episodes in the placebo group
(MD1.30, 95%CI 0.39 to 2.21). Overall, we judged the evidence
to be low quality, downgrading for risk of bias and inconsistency
between the two studies.
Javadi 2010 reported visual acuity at final follow-up, which was
approximately 18months (range 2 to 33months follow-up) (Table
7). The MD in visual acuity between the two groups was 0.04
(95% CI -0.10 to 0.18).
Neither study reported quality of life or costs.
Topical tacrolimus versus topical steroid in people
undergoing normal-risk keratoplasty
One study compared topical tacrolimus with topical steroid in 32
normal-risk keratoplasty participants and reported at 6 months
follow-up (Reinhard 2005) (Table 8).
The graft survived in all of the 12 treated participants and 20
control participants. The immune reactions were also very rare: 0
out of 12 versus 2 out of 20 in the two groups, respectively (RR
0.32, 95% CI 0.02 to 6.21).
We judged this to be low-quality evidence, downgrading for risk
of bias and imprecision.
Visual acuity, quality of life, and costs were not reported.
Adverse effects
Systemic MMF
We saw a range of adverse effects with MMF, which we have
summarised in Table 9.
Topical CsA
Sinha 2010 reported that “Overall, topical cyclosporine A 2% was
well tolerated by all the patients included in this study. There were
no reports of ocular irritation. There was no epithelial toxicity in
the form of corneal erosions or superficial punctuate keratopathy
in any of the patients”.
Javadi 2010 reported “No significant complications occurred dur-
ing the study. As mentioned, only one case from group 1 [CsA
group] was excluded due to medication intolerance”.
Zhang 2009 reported that the incidence of adverse events was
similar in the topical CsA (1 case) and placebo groups.
Systemic CsA
We have summarised adverse effects seen with systemic CsA in
Table 10.
Tacrolimus
Eight participants withdrew due to local side effects in the inter-
vention group. Reinhard 2005 reported adverse events such as su-
perficial punctate keratitis (8 out of 20 versus 8 out of 20), injec-
tion of the conjunctiva (6 out of 20 versus 2 out of 20), burning
sensation (6 out of 20 versus 0 out of 20), superficial opacification
(2 out of 20 versus 1 out of 20), and erosion (1 out of 20 versus
0 out of 20), in the experimental and control groups, respectively.
There were no significant differences between the two arms except
a burning sensation (see Table 11).
D I S C U S S I O N
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Summary of main results
We included six studies conducted in Germany, Iran, India, and
China. Three studies were conducted in people undergoing high-
risk keratoplasty and investigated three different comparisons: sys-
temic mycophenolate mofetil (MMF) versus no MMF; systemic
MMF versus systemic cyclosporine A (CsA); and topical CsA ver-
sus placebo. One study compared topical tacrolimus to topical
steroid in people with normal-risk keratoplasty, and two studies
compared topical CsA to placebo in people experiencing graft re-
jection after normal-risk keratoplasty. All participants in these tri-
als received additional steroid treatment.
There was uncertainty as to the effect of systemic MMF, systemic
CsA, or topical CsA on both clear graft survival and graft rejection
in people with high-risk keratoplasty.
Topical CsA probably does not have an effect on clear graft sur-
vival in people experiencing graft rejection after normal-risk ker-
atoplasty compared to placebo. There were inconsistent findings
on graft rejection.
There was uncertainty as to the relative effects of topical tacrolimus
to topical steroid.
Adverse effects were common with systemic MMF, but less com-
mon with topical treatments CsA and tacrolimus.
Overall completeness and applicability of
evidence
The included studies have addressed the main objectives of the
review including graft survival and incidence of graft rejection at 12
months. However, the question about other outcomes including
best-corrected visual acuity, quality of life, and cost-effectiveness
analysis have not been answered.
The evidence from this review came from both normal- and high-
risk keratoplasty populations, and therefore can be applied to both
of these populations.
Quality of the evidence
Overall, we rated the quality of evidence from the included studies
from low to moderate due tomethodological limitations in the in-
cluded trials and imprecision in the summary estimates. For some
analyses, results of individual trials were inconsistent. Publication
bias was also a possibility, but we were unable to assess this due to
the low number of trials for each comparison.
Two trials failed to report the information on interventions ade-
quately (Reinhard 2001; Reinhard 2005). Dosage and duration of
therapy should be considered when evaluating the effectiveness of
immunosuppressants, but we could not do this due to the small
number of included trials.
Potential biases in the review process
As the review included fewer than 10 trials, we were unable to in-
vestigate publication bias using a funnel plot. We searched English
and Chinese databases only, but not other language databases.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Currently there is insufficient evidence to ascertain which im-
munosuppressant is better for penetrating keratoplasty. There was
uncertainty as to the effects of systemic MMF, systemic CsA, or
topical CsAonboth clear graft survival and graft rejection inpeople
with high-risk keratoplasty. Topical CsA probably does not have an
effect on clear graft survival in people experiencing graft rejection
after normal-risk keratoplasty compared to placebo. There were
inconsistent findings on graft rejection. There was uncertainty as
to the relative effects of topical tacrolimus to topical steroid. Ad-
verse effects were common with systemic MMF, but less common
with topical treatments CsA and tacrolimus.
Implications for research
Large, randomised, placebo-controlled, double-masked trials us-
ing polyvinyl alcohol as the vehicle of topical CsA should be con-
ducted by a third party who has no conflict of interest to eval-
uate the effectiveness of immunosuppressant and adverse events
that may occur. For all immunosuppressants, future studies should
take into account the following factors: the study should be pow-
ered to detect important clincial differences, and methods (ran-
domisation procedure, allocation concealment, masking of partic-
ipants and outcome assessors) should be performed and reported
in detail. Other factors impacting study quality include baseline
of participants and the manufacturer, composition, dosage, and
course of treatment of the drugs. The method of outcomes detec-
tion should be designed, performed, and reported carefully; ITT
analysis should be applied to the outcomes when there are missing
participants due to drop-out or loss to follow-up. The outcomes
best-corrected visual acuity, quality of life, and cost-effectiveness
analysis should be assessed. Follow-up should be at least one year.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Birnbaum 2009
Methods Multicentre (9 centres)
Parallel-group RCT, unclear how many eyes included
Participants Country: Germany
Number of participants enrolled: 98
Number of participants per-protocol: 87
Average age (range): 59 years (not reported)
Sex: 47% women
Inclusion criteria:
High-risk keratoplasty, which was defined as ”repeat keratoplasty, graft position close to
the limbus, presence of three or four quadrants with deep vascularisation, transplantation
of a highly immunogenic graft (eg, central limbokeratoplasty), severe atopic dermatitis,
and steroid-response glaucoma“
Exclusion criteria:
• herpetic keratitis or other infectious corneal diseases
• other contraindications for systemic immunosuppression
◦ history of acute or chronic systemic infections
◦ peptic ulcer disease
◦ malignant disorders
◦ inadequate contraceptive measures/pregnancy
◦ age under 18 years
Interventions Intervention:
• MMF (systemic) (n = 57)
Comparator:
• No MMF (n = 41)
Participants received MMF at a fixed dosage (2 x 1000 mg daily) for 6 months postop-
eratively. Thereafter, they took 2 x 500 mg MMF daily for 2 weeks
Participants in both groups received systemic and topical corticosteroids: fluocortolone
at 1 mg/kg body weight per day, tapered over 3 weeks, and prednisolone acetate 1% eye
drops at 5 times a day, tapered over 5 months
Outcomes 1. Clear graft survival
2. Immune reactions
3. Side effects
4. Endothelial cell loss of the drug
Method and times of measuring the out-
comes
Postoperative examination was performed after 6 weeks, 3, 6, 9, 12, 18, and 24 months,
and then yearly, including visual acuity, slit-lamp examination, specular microscopy of
the graft endothelium, determination of intraocular pressure, and fundus examination.
Adverse events and possible systemic side effects were monitored (in cooperation with
each participant’s general practitioner) by means of a standard list of questions. The
mean follow-up time was 34.9 ± 16.3 (mean ± SD) months
All participants were monitored for efficacy postoperatively. A scoring system was not
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Birnbaum 2009 (Continued)
used. If opacities could not be detected in any of the corneal layers regarding the central
3 mm, the grafts were considered clear
Funding source and statement of interest Roche Pharma AG, Grenzach-Wyhlen, Germany, for financial support of the study.
There was no declaration of interest in the article
Notes Date study conducted: June 2000 to August 2006
Trial registration number: NCT00411515
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation was performed by drawing
a lot.
Allocation concealment (selection bias) Unclear risk Not used.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not used.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 11 participants withdrew from the study:
7 in the MMF group and 4 in the control
group. Of the 11 participants, 9 withdrew
due to protocol deviation, 2 due to side
effects from the MMF
Selective reporting (reporting bias) Unclear risk Not mentioned.
Other bias High risk ”Study recruitment was stopped prema-
turely due to a statistically significant result
from the interim evaluation once 2/3 of the
patients had been recruited.“ Page 2066
Javadi 2010
Methods Single-centre
Parallel-group RCT, 1 eye per person included
Participants Country: Iran
Number of participants: 43
Average age (range): 34 years (17 to 59)
Sex: 49% women
Inclusion criteria:
People who had at least 1 episode of graft rejection after penetrating keratoplasty. Graft
rejection reaction was defined as ”the presence of subepithelial infiltration, the presence
of keratic precipitates with or without anterior chamber reaction, or graft oedema in a
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Javadi 2010 (Continued)
previously clear graft with or without keratic precipitates or anterior chamber reaction.
In the case of graft oedema without keratic precipitates or anterior chamber reaction,
oedema reversal after taking corticosteroids differentiated graft rejection from endothelial
decompensation“
Exclusion criteria:
• other ocular pathologies that could increase the risk of graft rejection and failure
◦ iridocorneal adhesion
◦ corneal vascularisation
◦ previous graft failure
◦ high intraocular pressure
◦ uveitis
◦ herpetic eye disease
Interventions Intervention:
• CsA (topical) 2% prepared in olive oil (n = 22)
Comparator:
• Placebo (olive oil) (n = 21)
Upon graft rejection, the participants were given CsA or placebo 4 times a day for 6
months in addition to corticosteroid treatment. Based on the severity of graft rejection
reaction, corticosteroid treatment consisted of 0.1% topical betamethasone every 1 hour
during waking hours with its ophthalmic ointment during sleep, alone or in combination
with 1 mg/kg oral prednisolone for 2 weeks. The topical corticosteroid was gradually
tapered off over 2 weeks after resolution of the rejection episode, which was defined as
complete clearance of keratic precipitates or anterior chamber reaction, or both. Graft
rejection episodes recurring after the termination of CsAwere treatedwith corticosteroids
as usual
Outcomes 1. Previous, concurrent, and subsequent numbers of rejection episodes
2. Duration of corticosteroid administration and time to resolution of the rejection
episode for which 2% topical CsA or placebo was started
3. Time interval from the initiation of study to the first recurrence of subepithelial or
endothelial graft rejection
Method and times of measuring the out-
comes
The participants were followed up every week until complete resolution of the graft
rejection episode and then every month for 3 months, every 2 months for 1 year, and
every 6months onwards. In the case of visual acuity reduction or eye redness, participants
had access to the ophthalmologist; participants were examined between the follow-up
examinations as necessary
Funding source and statement of interest Funded by Sina Daru Pharmacy Co, Tehran, Iran.
Competing interests: Author Ahmad Karbasian is the executive manager of Sina Daru
Pharmacy Co, from which 2% topical CsA and placebo were procurred. The other
authors had no financial or propriety interest in any of the materials used in this study
Notes Date study conducted: not reported
Trial registration number: NCT01028443
Risk of bias
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Javadi 2010 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ”randomised, double-blind clinical trial“
was mentioned, but lack of detailed infor-
mation
Allocation concealment (selection bias) Unclear risk Allocation concealment was not men-
tioned.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Both the participants and the ophthalmol-
ogist were masked.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Only one participantwas excluded, because
of intolerance to the medication given
Selective reporting (reporting bias) Unclear risk Not mentioned.
Other bias Unclear risk Not mentioned.
Reinhard 2001
Methods Single-centre
Parallel-group RCT, unclear how many eyes included
Participants Country: Germany
Number of participants: 56
Average age (range): 55 years (18 to 87)
Sex: 48% women
Inclusion criteria:
High-risk keratoplasty, which was defined by ”the presence of deep vascularization in
three or four quadrants, a history of previous keratoplasty, position of the graft close to
the limbus, transplantation of a highly immunogenic graft (limbokeratoplasty), severe
atopic dermatitis or steroid response glaucoma“
Exclusion criteria:
• under 18 years of age
• history of malignant tumors
• acute or chronic systemic infections
• acute peptic ulcer disease
• pregnancy/insufficient contraceptive measures
• herpetic eye disease or any other kind of acute corneal infection
Interventions Intervention:
• CsA (systemic) (n = 27)
Comparator:
• MMF (systemic) (n = 29)
MMF was administered in a daily dose of 2 × 1 g; the CsA dose was adjusted according
to blood trough levels, with a target of 120 to 150 ng/ml (monoclonal TDx, Abbott
21Immunosuppressants for the prophylaxis of corneal graft rejection after penetrating keratoplasty (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Reinhard 2001 (Continued)
Exsym). After 6 months, immunosuppressive medication was tapered within 2 weeks.
Additionally, all participants except those with steroid-induced glaucoma received cor-
ticosteroids systemically (1 mg/kg body weight fluocortolone, tapered within 3 weeks
postoperatively) and topically (5 drops prednisolone acetate 1% daily after epithelial
consolidation, tapered within 5 months)
Outcomes 1. Graft failure
2. Immune reactions
3. Side effects: hepatotoxicity, arterial hypertension, gingiva problems,
neurovegetative disorders, Hodgkin’s lymphoma, recurrence of acoustic neurinoma,
exacerbation of atopic dermatitis
4. Premature withdrawal of drug
Method and times of measuring the out-
comes
Postoperative visits were performed after 1, 3, 6, 9, 12, 24, and 36 months. Immune
reactions were diagnosed by endothelial precipitates adhering to graft endothelium with
(severe endothelial immune reactions) or without (mild endothelial immune reactions)
stromal oedema or by the presence of non-infectious stromal infiltration (stromal im-
mune reactions)
Endothelial cell loss was assessed only in participants with at least 3 postoperative en-
dothelial cell density values. Participants with endothelial immune reactions were ex-
cluded from this calculation. The individual mean loss of endothelial cells per day and
per square millimetre was derived from the postoperatively acquired endothelial values
of each participant individually. This was done by calculating the slope of the regression
line for each scatter plot of endothelial cell density values plotted against time
Funding source and statement of interest No information on funding source and declaration of interest
Notes Date study conducted: not reported
Trial registration number: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ”The 56 patients were randomised to re-
ceive CsA (27 patients) or MMF (29 pa-
tients)“, but no detailed information about
randomisation procedure
Allocation concealment (selection bias) Unclear risk Not mentioned.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not used.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Premature withdrawal from immunosup-
pressive prophylaxis occurred in 2 partic-
ipants in the CsA group (1 case of severe
gingival hyperplasia, 1 of hepatotoxicity),
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Reinhard 2001 (Continued)
and in 2 participants in theMMF group (1
diagnosis ofHodgkin’s lymphoma 1month
after keratoplasty, 1 case of dermatological
problems in a participant with severe atopic
dermatitis)
Selective reporting (reporting bias) Unclear risk Not mentioned.
Other bias High risk ”Study recruitment was stopped prema-
turely due to a statistically significant
result from the scheduled interim evalua-
tion“. Page 2064
Reinhard 2005
Methods Multicentre/single-centre: not reported
Parallel-group RCT, unclear how many eyes included
Participants Country: Germany
Number of participants: 40
Average age (range): 58 years in tacrolimus group and 70 years in steroid group (range
not reported)
Sex: 48% women
Normal-risk keratoplasty
Interventions Intervention:
• Tacrolimus (topical) 0.06% (n = 20)
Comparator:
• Prednisolone acetate (topical) 1% (n = 20)
Participants were treated with topical tacrolimus 0.06% 3 times per day for 6 months
postoperatively or 5 drops of prednisolone acetate 1% tapered within 6 months. All
participants received 1 mg/kg bodyweight/day of systemic fluocortolone tapered within
3 weeks postoperatively
Outcomes 1. Clear graft survival
2. Ratio of immune reactions
3. Side effects
Method and times of measuring the out-
comes
Controls of the graft at the slit-lamp were scheduled 7 weeks, 4, 12, and 18 months post-
operatively and thereafter annually. Endothelial immune reactions were diagnosed via
endothelial precipitates and stromal oedema, stromal immune reactions via subepithelial
infiltrates. Postoperative visits: trial authors did not describe the visit time in detail and
only stated that follow-up times of tacrolimus group and steroid group were 5.8 to 14.
8 and 9.1 to 13.3, respectively
Funding source and statement of interest Funding source was not mentioned and no declaration of interest
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Reinhard 2005 (Continued)
Notes Date study conducted: not reported
Trial registration number: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ”A randomised clinical pilot study“ was
mentioned in the article title, but there was
no information about the randomisation
procedure in the text
Allocation concealment (selection bias) Unclear risk Not performed.
Blinding (performance bias and detection
bias)
All outcomes
High risk Not performed.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Premature withdrawal of the drug occurred
in 8 participants due to local side effects
in the tacrolimus group, and all the partic-
ipants completed the study in accordance
with the protocol
Selective reporting (reporting bias) Unclear risk No information.
Other bias Unclear risk No information.
Sinha 2010
Methods Single-centre
Parallel-group RCT, 1 eye per person included
Participants Country: India
Number of participants: 84
Average age (range): 46 years (21 to 87)
Sex: 44% women
High-risk keratoplasty
Interventions Intervention:
• CsA (topical) 2% prepared in 1.4% polyvinyl (n = 42 randomised, n = 39
analysed)
Comparator:
• Polyvinyl alcohol (topical) 1.4% (n = 42 randomised, n = 39 analysed)
Additional treatment given to all participants: systemic fluocortolone 1 mg/kg body-
weight/ day tapered within 3 weeks postoperatively; acetazolamide 500 mg/day for 5
days postoperatively,
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Sinha 2010 (Continued)
Outcomes 1. Primary outcomes: occurrence of graft rejection, rejection-free interval, and the
reversal of graft rejection
2. Bullous keratopathy
3. Corneoiridic scars
Method and times of measuring the out-
comes
Subsequent follow-up was done at 1, 3, 6 months, and 1 year postoperatively. At each
follow-up, participants were evaluated on parameters of best-corrected visual acuity,
slit-lamp biomicroscopy for corneal and anterior segment evaluation, anterior chamber
reaction (flare and cells), corneal thickness, and intraocular pressure
Rejection was defined as the occurrence of 1 of the following:
1. development of an endothelial rejection line
2. new unilateral anterior chamber reaction with keratic precipitates and increasing
corneal oedema in a previously clear compact graft with visible aqueous cells
Funding source and statement of interest The study was funded by a financial grant from the Indian Council of Medical Research,
New Delhi, India
The authors reported that they had no financial, proprietary or competing interests
Notes Date study conducted: January 2002 to December 2004
Trial registration number: ISRCTN52781697
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A computer-generated sequence, block
randomisation strategy was used
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported
Blinding (performance bias and detection
bias)
All outcomes
Low risk The ocular pharmacologist was masked to
the outcome variables, and the results as-
sessor was masked
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No exclusion.
Selective reporting (reporting bias) Unclear risk No information.
Other bias Unclear risk No information.
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Zhang 2009
Methods Multicentre (4 centres)
Parallel-group RCT, unclear how many eyes included
Participants Country: China
Number of participants: 240
Average age (range): 18 to 65 years
Sex: F/M: 36/84 and 27/93, respectively
High-risk keratoplasty
Interventions Intervention:
• CsA (topical) 1% (n = 120)
Comparator:
• Placebo (n = 120)
CsA given as eye drops 4 ~ 6 times a day, 2 drops a time, total 6 months. In both groups,
1% dexamethasone eye drops 4 times a day, 1 ~ 2 drops a time. 2 weeks later 3 times a
day, 30 days later 2 times a day, 2 months later 1 time a day
Outcomes Primary outcomes:
1. Clarity of the corneal graft, with no ciliary congestion, clear corneal graft, normal
thickness was rated as effective
2. Rejection rate and time of onset of rejection
Secondary outcomes:
1. Result of treatment for rejection
2. Adverse effects
Method and times of measuring the out-
comes
Follow-up over 180 days.
Funding source and statement of interest The funding source was not mentioned, but two of the authors came from the Huabei
Pharmaceutical Group New Drug Development LTD., where the experimental drug is
made
The declaration of interest was not provided.
Notes Date study conducted: not reported. We telephoned the first author, Professor Zhang,
and known that the study was conducted between July, 2003 to August, 2004
Trial registration number: not registered
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number table was mentioned, but
procedure not described in detail
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
Low risk Placebo used and adequately masked.
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Zhang 2009 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Treatment not completed in 1 case in the
CsA group (1/120) and 9 cases in the con-
trol group (9/120)
Selective reporting (reporting bias) Unclear risk No information.
Other bias Unclear risk No information.
CsA: cyclosporine A
MMF: mycophenolate mofetil
RCT: randomised controlled trial
SD: standard deviation
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
He 1999 Claimed to be a RCT, but was identified in a telephone interview with the original author as a non-RCT
Liu 2007 Claimed to be a RCT, but was identified in a telephone interview with the original author as a non-RCT
Lu 2009 This study, which compared local and systemic administration of glucocorticoids, was not a RCT
NCT00553735 Trial assessed treatment of dry eye syndrome in people who had recently received a bone marrow transplant
Reinhard 1999 Participants with different conditions.
Wu 2001 Claimed to be a RCT, but was identified in a telephone interview with the original author as a non-RCT
Xi 2003 Claimed to be a RCT, but was identified in a telephone interview with the original author as a non-RCT
Ye 2004 Claimed to be a RCT, but was identified in a telephone interview with the original author as a non-RCT
Zhao 2005 Claimed to be a RCT, but was identified in a telephone interview with the original author as a non-RCT
Zhou 2008 A quasi-RCT, allocated participants by the number of birth date
RCT: randomised controlled trial
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Characteristics of ongoing studies [ordered by study ID]
NCT00409656
Trial name or title Prospective, randomised trial of basiliximab (Simulect) in the prophylaxis of high-risk keratoplasty patients
Methods Allocation: randomised
Control: active control
Endpoint classification: efficacy study
Intervention model: parallel assignment
Masking: open label
Primary purpose: prevention
Participants Inclusion criteria: high-risk keratoplasty
Exclusion criteria: normal-risk keratoplasty
Age minimum: N/A
Age maximum: N/A
Gender: both
Interventions Basiliximab
Outcomes Primary outcome: graft rejection
Secondary outcome: clear graft survival
Starting date December 2003
Contact information Thomas Reinhard, MD, Prof. (http://clinicaltrials.gov/show/NCT00409656)
Notes
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D A T A A N D A N A L Y S E S
Comparison 1. Topical CsA versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clear graft survival 2 283 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.96, 1.10]
A D D I T I O N A L T A B L E S
Table 1. Characteristics of included studies
Study Country Type of kerato-
plasty
Number of par-
ticipants (eyes)
Intervention Comparator Additional treat-
ment to all par-
ticipants
Birnbaum 2009 Germany High risk 98 enrolled, 87
per-protocol
MMF (systemic)
1 g b.i.d. for 6
months
No MMF Systemic fluocor-
tolone 1 mg/kg
bodyweight/
day taperedwithin
3 weeks postoper-
atively; pred-
nisolone acetate
1% eye drops 5
times/day, tapered
over 5 months
Javadi 2010 Iran Par-
ticipants enrolled
at first episode of
graft rejection
43 (43) CsA (topical) 2%
prepared in olive
oil q.i.d. for 6
months
Placebo (olive oil)
q.i.d. for 6months
Based on the
severity of graft
rejection reaction,
0.1% topical be-
tamethasone every
1 h during wak-
ing hours with its
ophthalmic oint-
ment during sleep,
alone (in the pres-
ence of subepthe-
lial infiltra-
tion or some scat-
tered keratic pre-
cipitates)
or in combina-
tion with 1 mg/kg
oral prednisolone
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Table 1. Characteristics of included studies (Continued)
for 2 weeks (in the
presence of rejec-
tion lines or graft
oedema overlying
the keratic precip-
itates). The top-
ical corticosteroid
was gradually ta-
pered off over 2
weeks after resolu-
tion of the rejec-
tion episode,
which was defined
as complete clear-
ance of keratic
precipitates or an-
terior chamber re-
action, or both
Reinhard 2001 Germany High risk 56 CsA (systemic)
target blood levels
120 ng/ml to 150
ng/ml
MMF(systemic) 1
g b.i.d.
Systemic fluocor-
tolone 1 mg/kg
bodyweight/
day taperedwithin
3 weeks postoper-
atively; pred-
nisolone acetate
1% eye drops 5
times/day, tapered
over 5 months
Reinhard 2005 Germany Normal risk 40 enrolled; in
FK 506 group,
8 with premature
withdrawal of the
drug
tacrolimus (topi-
cal) 0.06% t.i.d.
for 6 months
Prednisolone ac-
etate (topical) 1%
5 drops/day ta-
pered within 6
months
Systemic fluocor-
tolone 1 mg/kg
bodyweight/
day taperedwithin
3 weeks postop-
eratively; acetazo-
lamide 500 mg/
day for 5 days
postop
Sinha 2010 India High risk 84 (84) CsA (topical) 2%
prepared in 1.4%
polyvinyl alcohol
q.i.d. for 1 year
Polyvinyl alcohol
1.4%
Topical
prednisolone ac-
etate 1% eye drops
2 hourly during
wak-
ing hours for the
initial 2 weeks fol-
lowed by every 6
hours for 1 month
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Table 1. Characteristics of included studies (Continued)
and 4 times a day
for 1 year. Topi-
cal 0.3% ofloxacin
hydrochloride eye
drops 4 times a
day for the initial
1 month
Zhang 2009 China Participants with
graft rejection
240 par-
ticipants enrolled;
119 in the CsA
group and 111 in
the placebo group
per-protocol
CsA (topical) 1%
prepared in ? q.i.d.
for 6 months
Placebo (?) 0.1% dexametha-
sone
MMF: mycophenolate mofetil; CsA: cyclosporine A
b.i.d.: twice daily; t.i.d.: three times daily; q.i.d.: four times daily
Table 2. Systemic MMF versus no MMF in people undergoing high-risk keratoplasty
Outcome Systemic MMF No MMF RR (95% CI)
Clear graft survival at 3 years 40/50 (80.0%) 28/37 (75.7%) 1.06 (0.84 to 1.33)
Graft rejection (immune reac-
tions) at 3 years
8/50 (16.0%) 12/37 (32.4%) 0.49 (0.22 to 1.08)
Data from Birnbaum 2009
MMF: mycophenolate mofetil
RR: risk ratio
CI: confidence interval
Table 3. Systemic MMF versus systemic CsA in people undergoing high-risk keratoplasty
Outcome Systemic MMF Systemic CsA RR (95% CI)
Clear graft survival at 3 years 25/27 (92.6%) 21/25 (84.0%) 1.10 (0.90 to 1.35)
Graft rejection (immune reac-
tions) at 3 years
8/27 (29.6%) 5/25 (20.0%) 1.48 (0.56 to 3.93)
Data from Reinhard 2001
MMF: mycophenolate mofetil
CsA: cyclosporine A
RR: risk ratio
CI: confidence interval
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Table 4. Topical CsA versus placebo in people undergoing high-risk keratoplasty
Outcome Topical CsA Placebo RR (95% CI)
Graft rejection (immune reac-
tions) at 1 year
7/39 (17.9%) 7/39 (17.9%) 1.00 (0.39 to 2.58)
Data from Sinha 2010
CsA: cyclosporine A
RR: risk ratio
CI: confidence interval
Table 5. Topical CsA versus placebo in people undergoing high-risk keratoplasty (visual acuity)
Outcome Topical CsA Placebo MD (95% CI)
mean (SD) N mean (SD) N
Mean best-
corrected visual acu-
ity at 1 year
0.31 (0.18) 39 0.24 (0.17) 39 0.07 (-0.01 to 0.15)
Data from Sinha 2010
CsA: cyclosporine A
SD: standard deviation
MD: mean difference
CI: confidence interval
Table 6. Topical CsA versus placebo in people with graft rejection after normal-risk keratoplasty
Outcome Topical CsA Placebo RR (95% CI)
Graft rejection (immune reac-
tions) at 6 months
7/119 (5.9%) 17/111 (15.3%) 0.35 (0.14 to 0.87)
Data from Zhang 2009
CsA: cyclosporine A
RR: risk ratio
CI: confidence interval
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Table 7. Topical CsA versus placebo in people with graft rejection after normal-risk keratoplasty (visual acuity)
Outcome Topical CsA Placebo MD (95% CI)
mean (SD) N mean (SD) N
Mean best-
corrected visual acu-
ity at 18 months
0.23 (0.31) 22 0.19 (0.12) 21 0.04 (-0.10 to 0.18)
Data from Javadi 2010
CsA: cyclosporine A
SD: standard deviation
MD: mean difference
CI: confidence interval
Table 8. Topical tacrolimus versus topical steroid in people undering normal-risk keratoplasty
Outcome Topical tacrolimus Topical steroid RR (95% CI)
Clear graft survival at 6 months 12/12 (100%) 20/20 (100%) 1.00 (0.88 to 1.14)
Graft rejection (immune reac-
tions) at 6 months
0/12 (0%) 2/20 (10%) 0.32 (0.02 to 6.21)
Data from Reinhard 2005
RR: risk ratio
CI: confidence interval
Table 9. MMF: adverse effects
Category Study Details of adverse event MMF
Number of events/Num-
ber followed up
Control*
Number of events/Num-
ber followed up
Epithelial keratitis Birnbaum 2009 Not reported
Reinhard 2001 Not reported
High intraocular pres-
sure
Birnbaum 2009 Not reported
Reinhard 2001 Glaucoma 1/29 2/27
Major calcineurin-
inhibitor toxicity
Birnbaum 2009 Hyperglycaemia 7/57 4/41
Reinhard 2001 Hepatotoxicity 2/29 3/27
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Table 9. MMF: adverse effects (Continued)
Minor calcineurin-
inhibitor toxicity
Birnbaum 2009
Reinhard 2001 Gingival problems 0 3/41
Dose reductions due to
adverse events
Birnbaum 2009 Due to raised liver enzymes 2/57 0
Reinhard 2001 Not reported
Withdrawals and drop-
outs due to adverse
events
Birnbaum 2009 Gastrointestinal
disturbances (1)
Asthma, pruritus, and fa-
tigue (1)
2/57 0
Reinhard 2001 2/29 2/27
Birnbaum 2009 control group received systemic and topical corticosteroids same as MMF group.
Reinhard 2001 control group received systemic cyclosporine A.
MMF: mycophenolate mofetil
Other adverse effects reported in MMF group in Birnbaum 2009: Hyperlipidaemia (11), Infections (8), Tachycardia (4), Weight loss
(4), Fatigue (4), Weight gain (3), Insomnia (3), Headache (3), Malignancies (2), Myalgia (1), Renal colic (1), Myocardial infarction (1),
Erythema (1), Deterioration of atopic eczema (1), Muscular cramps (1), Paresthesia (1), Ostealgia (1), Agranulocytosis (1), Anaemia
(1).
Table 10. Systemic MMF versus systemic CsA: adverse effects
Study ID and compar-
isons
Side effects Number of events/
number followed up in
the experimental group
Number of events/
number followed up in
the control group
OR (95% CI)
Reinhard 2001
Systemic MMF versus
systemic CsA
Hepatotoxicity 2/29 3/27 0.6 (0.10 to 3.72)
Arterial hypertension 0/29 3/27 0.12 (0.01 to 1.17)
Gingiva problems 0/29 3/27 0.12 (0.01 to 1.17)
Neurovegetative
disorders
0/29 3/27 0.12 (0.01 to 1.17)
Hodgkin’s lymphoma 0/29 1/27 0.13 (0.00 to 6.35)
Recurrence of acoustic
neurinoma
1/29 0/27 6.90 (0.14 to 348.44)
Exacerbation of atopic
dermatitis
1/29 0/27 6.90 (0.14 to 348.44)
MMF: mycophenolate mofetil
CsA: cyclosporine A
OR: odds ratio
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CI: confidence interval
Table 11. Tacrolimus: adverse effects
Study ID and compar-
isons
Side effects Number of events/
number followed up in
the experimental group
Number of events/
number followed up in
the control group
OR (95% CI)
Reinhard 2005
Topical tacrolimus ver-
sus topical steroid
Superficial punctate 8/20 8/20 1.00 (0.29 to 3.49)
Injection of the conjunc-
tiva
6/20 2/20 3.38 (0.73 to 15.62)
Burning sensation 6/20 0/20 9.92 (1.79 to 55.04)
Superficial opacification 2/20 1/20 2.02 (0.20 to 20.62)
Erosion 1/20 0/20 7.39 (0.15 to 372.38)
OR: odds ratio
CI: confidence interval
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